Table 1.
Pharmacological Effects | Compound (Class) | Algal Source If Any) | Effective Concentration | Experimental Model (In Vivo/In Vitro) | Cellular Effects/Significant Findings | Signaling Pathways Involved | Pharmacological Markers | Reference |
---|---|---|---|---|---|---|---|---|
Antioxidant activity | Fucoxanthin (carotenoids) | Sargassum siliquastrum | 50 and 100 μM | H2O2-induced cell damage in kidney fibroblast cells | Attenuates oxidative stress | n.d. | ↓ROS level | [69] |
Fucoxanthin | 5, 10, and 50 μM | H2O2 induced BV2 microglial cells | Antioxidation | Antioxidant pathway | ↓ROS ↑SOD and GSH |
[36] | ||
Fucosterol, 3,6,17-trihydroxy-stigmasta-4,7,24(28)-triene and 14,15,18,20-diepoxyturbinarin (sterols) | Pelvetia siliquosa | A seven day-dose regimen at 30 mg/kg/day before carbon tetrachloride (CCl4) administration | Rat model | Antioxidation | n.d. | ↑SOD, CAT, and GPx | [71] | |
Fucosterol |
Eisenia bicyclis, brown alga |
25, 50, 100, 200, and 400 μM | RAW 264.7 murine macrophages (t-BHP stimulated) |
Protects against oxidative stress | n.d. | ↓ROS generation | [72] | |
Fucosterol |
Ecklonia stolonifera and Eisenia bicyclis; Brown algae |
25, 50, and 100 μM | tert-Butyl hydroperoxide- and tacrine-induced HepG2cell injury model | Antioxidation | n.d. | ↓ROS generation ↑GSH level |
[73] | |
Fucosterol |
Sargassum Binderi; brown alga |
3.125, 6.25, 12.5, 25, 50, and 100 μg /mL | Particulate matter-induced injury and inflammation in A549 human lung epithelial cells | Attenuates oxidative stress | ↓ROS level ↑SOD, CAT, and HO-1 in the cytosol, and NRF2 in the nucleus |
[74]. | ||
Glycoprotein | U. pinnatifida | SOD activity and Xox activity at a concentration of 5 mg/mL and 1 mg/mL, respectively | In vitro enzyme assay | ↑SOD and↓Xox | [75] | |||
Sulfated oligosaccharides |
Ulva lactuca and Enteromorpha prolifera;
green algae |
150 mg/kg·day | Aging model (male senescence-accelerated prone (SAMP8) and male senescence resistant (SAMR1) mice) | Antioxidantion | n.d. | ↑GSH, SOD, CAT, telomerase levels, ↑Total antioxidant capacity, ↓MDA and AGEPs |
[96] | |
Anti-inflammatory activity | Fucoxanthin | 5, 10, and 50 μM | Aβ42-induced BV2 microglia cells | Anti-inflammation | MAPK pathway | ↓iNOS, COX-2 ↓TNF-α, IL-6, IL-1β, PGE2 ↓JNK, ERK, and p38 MAPK phosphorylation |
[36] | |
Fucoxanthin | - | LPS-activated BV-2 microglia | Anti-inflammation and antioxidation | Akt/NF-κB and MAPKs/AP-1 pathways; PKA/CREB pathway |
↓iNOS, COX-2, ↓TNF-α, IL-6, PGE2, NO, ROS ↓IL-6, TNF-α, iNOS, and COX-2 mRNA expression ↓Akt, NF-κB, ERK, p38 MAPK and AP-1 phosphorylation ↑Nrf2, HO-1 ↑PKA, CREB ↑BDNF |
[70] | ||
Fucosterol |
E. bicyclis; brown alga |
5–20 μM for NO | RAW 264.7 murine macrophages (t-BHP 200 μM, LPS-1μM stimulated) |
↓Inflammatory response | ↓NF-κB pathway | ↓NO production ↓iNOS and COX-2 |
[72] | |
Fucosterol | U. pinnatifida | 10, 25, or 50 μM | LPS-induced RAW 264.7 macrophages and THP-1 human monocyte cell line | ↓Inflammatory response | ↓NF-κB pathway | ↓iNOS, TNF-α, and IL-6 ↓DNA binding ↓phosphorylation of NF-κB, MKK3/6 and MK2 |
[83] | |
Fucosterol | Hizikia fusiformis | 1–10 μM | CoCl2 induced hypoxia in keratinocytes | ↓Inflammatory response | n.d. | ↓IL-6, IL-1β and TNF-α ↓pPI3K and pAkt and HIF1-α accumulation |
[82] | |
Fucosterol | Panida. australis | 0.004,0.2, and 10 μM | LPS or Aβ-induced BV2 (microglial) cells | Protects against LPS or Aβ-mediated neuroinflammation | n.d. | ↓IL-6, IL-1β, TNF-α, NO, and PGE2 | [85] | |
Fucosterol |
S. Binderi; brown alga |
3.125, 6.25, 12.5, 25, 50, 100 μg/mL | Particulate matter-induced injury and inflammation in A549 human lung epithelial cells |
↓Inflammatory response | n.d. | ↓COX-2, PGE2, TNF-α and IL-6 | [74] | |
Dieckol (phlorotannin) | E. cava | 50–300 µg/mL | LPS-stimulated murine BV2 microglia | Anti-inflammation and antioxidation | p-38 MAPK/ NF-κB pathway | ↓NO and PGE2; ↓iNOS and COX-2; ↓IL-1β and TNF-α; ↓ROS |
[86] | |
Phloroglucinol, eckol, dieckol, 7-phloroeckol, phlorofucofuroeckol A and dioxinodehydroeckol (phlorotannin) |
E. bicyclis; brown alga |
5–20 μM for NO | LPS-stimulated RAW 264.7 murine macrophages | ↓Inflammatory response | ↓NF-κB pathway | ↓NO production | [72] | |
Phlorofucofuroeckol A | E. stolonifera | 20 μM | LPS-activated BV2 and primary microglial cells | Anti-inflammation | NF-κB, JNKs, p38 MAPK, and Akt pathways | ↓NO and PGE2; ↓iNOS and COX-2; ↓IL-1β, IL-6 and TNF-α; ↓NF-κB activation and IκB-α degradation ↓JNK, p38, and Akt |
[87] | |
Phlorofucofuroeckol B (phlorotannin) | E. stolonifera | 10–40 µM | LPS-stimulated murine BV2 microglia | Anti-inflammation | IκB-α/NF-κB and Akt/ERK/JNK pathways | ↓TNF-α, IL-1β and IL-6; ↓COX-2 and iNOS ↓NF-κB activation and IκB-α degradation ↓Akt, ERK, and JNK phosphorylation |
[88] | |
8,8’-bieckol (phlorotannin) | E. cava | LPS-stimulated primary macrophages and RAW 264.7 macrophages & LPS-induced septic mice |
Anti-inflammation; Protects mice from endotoxin shock | NF-κB pathway | ↓NO and PGE2; ↓iNOS mRNA and protein expression; ↓IL-6; ↓Transactivation of NF-κB and nuclear translocation of the NF-κB p65 subunit ↓ROS |
[90] | ||
6,6′-bieckol (phlorotannin) | E. stolonifera | LPS-stimulated BV2 and murine primary microglial cells | Anti-inflammation | IκB-α/NF-κB and JNK/p38 MAPK/Akt pathways | ↓COX-2 and iNOS; ↓NO and PGE2, ↓IL-6 ↓Transactivation of NF-κB and nuclear translocation of the NF-κB p65 subunit ↓Akt, JNK and p38 MAPK phosphorylation |
[89] | ||
Fucoidan (sulfated polysaccharide) | Brown seaweed | 25, 50, and 100 µg/mL | LPS-stimulated murine BV2 microglia | Anti-inflammation | NF-κB and JNK/p38 MAPK/Akt pathways | ↓NO and PGE2; ↓COX-2, iNOS and MCP-1; ↓TNF-α and IL-1β; ↓NF-κB activation; ↓Akt, ERK, p38 MAPK and JNK phosphorylation |
[92] | |
Fucoidan | - | 125 µg/mL | LPS-activated primary microglia | Anti-inflammation | n.d. | ↓TNF-α and ROS | [93] | |
κ-carrageenan oligosaccharides and desulfated derivatives | Red algae | LPS-activated microglia | Anti-inflammation | n.d. | ↓TNF-α | [94] | ||
Sulfated oligosaccharides |
U. lactuca and E. prolifera;
green algae |
150 mg/kg·day | Aging model (male senescence-accelerated prone (SAMP8) and male senescence resistant (SAMR1) mice) | ↓Inflammatory response | n.d. | ↓IFN-γ, TNF-α, and IL-6 | [96] | |
Alginate-derived oligosaccharide | Brown algae | 50–500 µg/mL | LPS/Aβ-stimulated BV2 microglia | Anti-inflammation | TLR4/NF-κB signaling pathway | ↓NO and PGE2; ↓COX-2 and iNOS; ↓TNF-α, IL-6 and IL-12; ↓TLR4; ↑NF-κB/p65 subunit translocation |
[97] | |
Seleno-polymannuronate | Brown algae | 0.8 mg/mL | LPS-activated primary microglia and astrocytes; mouse model of acute inflammation |
Anti-inflammation | NF-κB and MAPK signaling | ↓NO and PGE2; ↓COX-2 and iNOS; ↓TNF-α, IL-1β and IL-6; ↑IκB-α, p65, p38, ERK and JNK phosphorylation |
[98] | |
Sargachromenol (plastoquinone) | Sargassum micracanthum | 30.2 μM (IC50) | LPS-stimulated RAW 264.7 macrophages | Anti-inflammation | NF-κB signaling | ↓NO and PGE2; ↓COX-2 and iNOS; ↑IκB-α |
[99] | |
Sargaquinoic acid (plastoquinone) | Sargassum siliquastrum | LPS-stimulated RAW 264.7 macrophages | Anti-inflammation | NF-κB signaling | ↓NO; ↓iNOS; ↑IκB-α; ↓nuclear translocation of NF-κB; ↓JNK1/2 MAPK |
[100] | ||
Floridoside (glycerol glycosides) |
Laurencia undulate; red alga |
50 μM | LPS-stimulated murine BV2 microglia | Anti-inflammation | MAPK Signaling | ↓NO, ROS; ↓iNOS and COX-2; ↓p38 MAPK and ERK phosphorylation |
[101] | |
Glycoprotein | U. pinnatifida | COX-1 and COX-2 inhibition with IC50 values of 53.03 ± 1.03 μg/mL and 193.35 ± 3.08 μg/mL, respectively | LPS-stimulated RAW 264.7 macrophages | Anti-inflammation | n.d. | ↓COX-1 and COX-2 ↓NO |
[75] | |
Caulerpin (bisindole alkaloid) | Caulerpa racemosa | 100 µM/kg body wt | Capsaicin-induced ear edema and carrageenan-induced peritonitis | Inhibition of nociception | n.d. | n.d. | [130] | |
Caulerpenyne (sesquiterpene) |
C. prolifera and C. racemosa |
5.1 μM | Lipoxygenase (LOX) enzyme activity assay | Inhibitory activity against LOX | - | Un-competitive type of inhibition | [131] | |
Aquamin (multi-mineral complex) | Lithothamnion corallioides; red alga | LPS-stimulated, glial-enriched primary cultures of rat cortex | Anti-inflammation | n.d. | ↓TNF-α and IL-1β | [132] | ||
Anticholinesterase activity | Fucosterol and 24-hydroperoxy 24-vinylcholesterol | E. stolonifera | IC50 values of 421.72 ± 1.43, 176.46 ± 2.51 µM, respectively | In vitro enzymatic assay | ↓BChE activity | - | Selective inhibition of BChE | [114] |
Fucosterol | Panida australis | inhibition against AChE (10.99–20.71%) and BChE (4.53–17.53%) with concentrations ≤ 56 μM, | In vitro enzymatic assay | ↓AChE and BChE activities | - | Nonselective cholinesterase inhibition | [85] | |
Fucosterol | Sargassum horridum | - | In vitro enzymatic assay | ↓AChE activity | - | Non-competitive inhibition | [115] | |
Fucoxanthin | - | IC50 value 1.97 mM | In vitro BChE activity assay | ↓BChE activity | Mixed inhibition type | [116]. | ||
Fucoxanthin | Brown seaweed | IC50 value of 81.2 μM | In vitro AChE activity assay; Molecular docking analysis |
↓AChE activity | Fucoxanthin likely interacts with the peripheral anionic site within AChE | Non-competitive manner | [117] | |
α-Bisabolol | Padina gymnospora | IC50 value < 10 μg/mL | In vitro enzymatic assay | ↓AChE and BChE activity | - | - | [118] | |
Glycoprotein | U. pinnatifida | AChE and BChE inhibitory activities with IC50 values of 63.56 ± 1.86 and 99.03 ± 4.64, respectively | In vitro enzymatic assay | ↓AChE and BChE activity | - | - | [75] | |
Phloroglucinol, dibenzo [1,4] dioxine-2,4,7,9-tetraol and eckol |
Ecklonia maxima; Brown alga | IC50 value: 76.70 to 579.32 μM | In vitro AChE activity assay | ↓AChE activity | - | - | [119] | |
Dieckol and phlorofucofuroeckol | E. cava | Ethanol-intoxicated memory impairment in mice | ↓AChE activity | n.d. | ↑Acetylcholine | [120] | ||
Sargaquinoic acid and sargachromenol (plastoquinones) |
Sargassum sagamianum | IC50 value for anti-AChE: 23.2 and 32.7 μM, respectively; IC50 value for anti-BChE of sargaquinoic acid 26 nm |
In vitro ChE activity assay | Sargaquinoic acid shows potent inhibitory activity against BuChE and moderate inhibitory activity against AChE | -. | - | [121] | |
(5E,10Z)-6,10,14-trimethylpentadeca-5,10-dien-2,12-dione and (5E,9E,13E)-6,10,14-trimethylpentadeca-5,9,13-trien-2,12-dione (Sesquiterpenes) |
S. sagamianum | IC50 values of 65.0 and 48.0, and 34.0 and 23.0 μM, respectively | In vitro ChE activity assay | Moderate inhibitory activity against AChE and BuChE | - | - | [133] | |
Anti-amyloidogenic and aggregation inhibition activity | Fucoxanthin | E. stolonifera and U. pinnatifida | ↓β-secretase activity; Binding energy (-7.0 kcal/mol) |
- | mixed-type inhibition | [134] | ||
Fucoxanthin | - | 0.1–30 μM | Suppresses the formation of Aβ1-42 fibrils and Aβ1–42 oligomers, and inhibits Aβ aggregation | - | - | [135] | ||
Fucoxanthin | - | 2 μM | ThT assay | Inhibits Aβ1-42 fibril and aggregate formation | - | - | [136] | |
Fucosterol | E. stolonifera and U. pinnatifida | 10–100 μM (IC50 value of 64.12 ± 1.0 μM) | In vitro enzyme assay; In silico analysis |
↓β-secretase activity; Binding energy (−10.1 kcal/mol) |
- | Noncompetitive inhibition | [134] | |
α-Bisabolol | Padina gymnospora | 5 μg/mL | Thioflavin T (ThT), Confocal laser scanning microscopy (CLSM) analysis, Transmission electron microscopy (TEM), Fourier transform infrared (FTIR) spectroscopic analysis and molecular dynamics simulation | Prevents oligomers formation as well as disaggregates the matured fibrils | - | - | [137] | |
Glycoprotein | U. pinnatifida | IC50 values of 73.35 ± 2.54 μg/mL | In vitro enzymatic assay | ↓BACE1 activity | - | - | [75] | |
Cholesterol homeostasis and Aβ clearance activity | Fucosterol | - | 100 and 200 μM (HEK293 cell cultures); 100 or 200 μM (macrophages and HepG2, H4IIE, and Caco2 cells) |
HEK293 cell cultures (Reporter system); THP-1-derived macrophages; Caco-2 cells HepG2 cells |
Reverses cholesterol transport. No accumulation of triglyceride in HepG2 |
n.d. | Dual-LXR agonist (LXR-α and LXR-β) ↑ABCA1, ABCG1, and ApoE; ↑Intestinal NPC1L1 and ABCA1; ↑Insig-2a, that delays nuclear translocation of SREBP-1c |
[138] |
Saringosterol | Sargassum fusiforme | 30 μM | Luciferase reporter assay system; HEK293T, THP-1 monocytes, HepG2, RAW264.7, THP-1 macrophages and Caco-2 cells |
n.d. | n.d. | Selective LXRβ agonist; ↑ABCA1, ABCG1, and SREBP-1c |
[139] | |
Alginate-derived oligosaccharide | Marine brown algae | BV2 microglial cells | Microglial phagocytosis of Aβ | Toll-like receptor signaling | ↑TLR4 | [97]. | ||
Monoamine oxidase inhibition and affinity to dopaminergic receptors | Phlorofucofuroeckol-A and dieckol (phlorotannin) | - | In vitro enzyme assay and functional assay for GPCR screening; Docking analysis | ↓hMAO activity; D3R and D4R stimulation |
- | - | [140]. | |
Antiaging | Sulfated oligosaccharides |
U. lactuca and E. prolifera;
green algae |
150 mg/kg/day | Aging model (male senescence-accelerated prone (SAMP8) and male senescence resistant (SAMR1) mice) | Antioxidant and anti-inflammation | n.d. | ↑GSH, SOD, CAT, telomerase levels, ↑Total antioxidant capacity, ↓MDA and AGEPs ↓IFN-γ, TNF-α, and IL-6 ↑BDNF and ChAT; ↑Sirt1, ↑p53 and FOXO1 |
[96] |
Fucosterol | Hizikia fusiformis | 50 µg/mL | Culture model of C. elegans | Extends lifespan | ↑Antioxidant mechanism | n.d. | [141] |
n.d.: not defined; -: information not available.